Microdose GLP-1 · Compounded
Microdose Semaglutide
Prescription only. Prescribed only if a licensed provider determines it is appropriate for you.
Safety, risks & side effects
Review these risks with a licensed provider and read the full prescribing information before starting.
Boxed warning: In rodent studies, semaglutide caused thyroid C-cell tumors. It is not known whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Do not use if you or a family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects
- Nausea
- Diarrhea or constipation
- Vomiting
- Abdominal pain
- Fatigue
Serious risks
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems
- Low blood sugar, especially with other diabetes medicines
- Kidney problems related to dehydration
- Serious allergic reactions
Do not use if you have
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious allergy to semaglutide
- Pregnancy or breastfeeding
Compounded and microdose GLP-1 medications are not FDA approved. The FDA does not review compounded medications for safety, effectiveness, or quality before marketing.
Microdosing is not an FDA-approved dosing regimen. Medications are only issued when clinically appropriate after a provider evaluation.